Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts. Show more
451 D Street, Boston, MA, 02210, United States
Market Cap
73.48M
52 Wk Range
$2.66 - $16.00
Previous Close
$3.85
Open
$3.95
Volume
3,152,444
Day Range
$3.76 - $4.49
Enterprise Value
72.87M
Cash
14.95M
Avg Qtr Burn
-11.65M
Insider Ownership
29.76%
Institutional Own.
17.01%
Qtr Updated
03/31/26
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
ELI-002 7P Details Pancreatic cancer, Cancer | Phase 3 Initiation | |
ELI-002 2P Details Solid tumor/s, Cancer | Phase 1 Update | |
ELI-002 7P (KRAS Vaccine) Details Metastatic Pancreatic Ductal Adenocarcinoma, Cancer | Phase 1 Initiation |
